Our project

Addressing the silent crisis of right-heart failure

Today, thousands of patients in Europe and the United States are living with right-heart failure, a condition often overshadowed by its left-heart counterpart.

congenital patients

0 k

of candidates for LVAD

0 %

Bridging the therapeutic gap

Right-heart failure has historically been underprioritized compared to left-heart failure, which presents more acute, life-threatening risks. However, evolving societal and medical priorities now place a greater emphasis on improving quality of life, not just extending survival.

Fontan Patients: The growing number of adults experiencing late-stage symptoms emphasizes the need for specialized, forward-thinking care. These patients have unique challenges, with progressive, multisystem complications linked to Fontan circulation, requiring new medical approaches due to limited current solutions. They can spend months with no symptoms although the damages are irreversible. These patients with end-stage heart failure typically experience symptoms around their 30s and succumb to the condition in their 40s.¹

Non-Congenital Patients: Invasive treatments often provide incomplete recovery, leaving significant gaps in patient outcomes. Current medical devices fail to address the irreversible damage caused by right-heart failure effectively, leaving patients with limited options until severe symptoms manifest.

Brightflow addresses both deficiencies, offering a sustainable alternative that would enable them to live longer and with the quality of life that they deserve.

¹For more about Fontan patients and their experiences, visit: https://canadianfontan.com/patient-stories/

Introducing our pump :
a game-changing device

Pump right, pump for life

Key features:

Long-Term support

Designed for sustainable performance.

Minimally invasive

Ensures reduced procedural risks and faster recovery.

Percutaneous delivery

Enables safe implantation without open-heart surgery.

Our pump is the first permanent percutaneous right-heart assist pump. This groundbreaking technology enables a synergistic operation of the pump with the native right heart.

How does it work?

Our pump comprises three main components:

Implantation System: An introducer and catheter ensure safe, precise delivery of the pump under echographic and radiological guidance via a femoral venous approach—eliminating the need for circulatory arrest.
Axial Pump: Utilizing magnetic coupling technology, the pump provides continuous flow rates of 2 to 5 L/min at pressures of 15 to 30 mmHg.
Electronic System: Powered by a subcutaneously implanted battery positioned in the pectoral area, the system provides 3 hours of autonomy, ensuring reliable performance for patients.

Why Brightflow?

It represents a paradigm shift in treating right-heart failure. With our percutaneous approach, patients can look forward to a future where quality of life is a standard.

The pump is currently under preclinical development – not available for human use.